ArticleCureus2026
Hidden in Plain Sight: Unmasking Hairy Cell Leukemia Through Structured Clinical Reasoning.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hairy cell leukemia (HCL) is a rare, indolent B-cell neoplasm that often presents with nonspecific laboratory findings, which can delay diagnosis. We report the case of a 75-year-old male with incidentally detected isolated thrombocytopenia and relative lymphocytosis. Peripheral blood smear showed lymphoid cells with cytoplasmic projections suggestive of hairy cells. Flow cytometry confirmed a dominant clonal population consistent with classical HCL, along with a small CD5+/CD23+ monoclonal B-cell population compatible with a chronic lymphocytic leukemia-like clone. Abdominal CT also revealed a renal lesion suspicious for carcinoma. This incidental finding led to the prioritization of urological intervention, illustrating how multidisciplinary management is coordinated when concurrent malignancies are present. The patient remains asymptomatic and under active surveillance for both conditions. Subtle hematologic abnormalities may indicate early stages of HCL, and internists play a crucial role in recognizing these early signs and initiating targeted diagnostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.